India Pharma Outlook Team | Tuesday, 24 March 2026
Uttar Pradesh pharma investment is gaining strong momentum as the state moves ahead with a INR2,500 crore plan to build a robust healthcare manufacturing ecosystem.
The initiative includes a bulk drug park in Lalitpur and a medical device park in Greater Noida, both designed to attract large-scale investment and reduce India’s dependence on imports.
The bulk drug park, spread across 1,500 acres in Lalitpur, will see an investment of around INR2,000 crore. It is expected to offer plug-and-play infrastructure, making it easier for pharma companies to set up operations quickly. The project is also projected to generate significant employment, with lakhs of jobs likely to be created once fully operational.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
In parallel, the medical device park in Greater Noida, planned over 350 acres, will involve an investment of about INR500 crore. Located near the upcoming Noida International Airport, the park is strategically positioned to support logistics and exports, strengthening India’s medical device manufacturing sector.
This Uttar Pradesh pharma investment push aligns with the broader goal of boosting domestic production of critical drugs and devices. By creating integrated infrastructure and simplifying approvals, the state aims to position itself as a key hub for pharma manufacturing in India.
Officials believe these projects will not only attract domestic and global players but also support long-term growth in the healthcare sector. With rising demand and policy support, Uttar Pradesh is working to build a competitive edge in bulk drug production and medical device manufacturing, reinforcing its role in India’s expanding pharma landscape.
.jpg)
.jpg)
